Related Experiment Videos
Immunomodulation of experimental APS: lessons from murine models
I Krause1, M Blank, Y Shoenfeld
1Department of Medicine B, Sheba Medical Center, Tel-Hashomer, Israel.
Lupus
|October 1, 1996
Summary
Murine models for Antiphospholipid Syndrome (APS) have advanced treatment research. Promising therapies include immunomodulation, IL-3, IVIG, antibiotics, and anticoagulants, potentially aiding future clinical trials.
Area of Science:
- Immunology
- Rheumatology
- Hematology
Background:
- Antiphospholipid Syndrome (APS) research has advanced with new murine models.
- These models replicate spontaneous or induced APS, aiding disease study.
Purpose of the Study:
- To evaluate various treatment modalities in established murine models of APS.
- To identify potential therapeutic strategies for human APS patients.
Main Methods:
- Utilized spontaneous and induced murine models of APS.
- Assessed treatments including immunomodulation (anti-idiotypic/anti-CD4 antibodies), IL-3, IVIG, ciprofloxacin, bromocriptine, aspirin, and low-molecular-weight heparin.
- Investigated bone marrow transplantation as a therapeutic approach.
Main Results:
- Immunomodulatory therapies, IL-3, IVIG, antibiotics, and anticoagulants showed promise.
- Bone marrow transplantation improved clinical and serological APS manifestations.
- These findings support further investigation in clinical trials.
Conclusions:
- Murine models are valuable for studying APS treatments.
- Several therapeutic strategies demonstrate potential for APS patient care.
- Further clinical trials are warranted to confirm efficacy in humans.